Enhanced platelet adhesion induces angiogenesis in intestinal inflammation and inflammatory bowel disease microvasculature by Rutella, S et al.
Introduction
Angiogenesis is an intricate process resulting in the generation
of novel vessels from pre-existing ones, through the promotion
of endothelial cell (EC) division, degradation of vascular base-
ment membrane and surrounding extracellular matrix, and EC
migration [1]. Angiogenesis is tightly regulated by a balance
between expression and function of pro-angiogenic and anti-
angiogenic mediators. Vascular endothelial growth factor
(VEGF) is recognized as a potent pro-angiogenic cytokine and is
secreted by monocytes/macrophages, EC and a variety of other
cell types [2]. Interleukin (IL)-8 exerts direct angiogenic effects
on EC in vitro and in vivo. Colonic mucosal IL-8 is up-regulated
in Crohn’s disease in direct correlation with the degree of
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Abstract
Although angiogenesis is viewed as a fundamental component of inflammatory bowel disease (IBD) pathogenesis, we presently lack
a thorough knowledge of the cell type(s) involved in its induction and maintenance in the inflamed intestinal mucosa. This study aimed
to determine whether platelet (PLT) adhesion to inflamed intestinal endothelial cells of human origin may favour angiogenesis.
Unstimulated or thrombin-activated human PLT were overlaid on resting or tumour necrosis factor (TNF)--treated human intestinal
microvascular endothelial cells (HIMEC), in the presence or absence of blocking antibodies to either vascular cell adhesion molecule
(VCAM)-1, intercellular adhesion molecule (ICAM)-1, integrin v3, tissue factor (TF) or fractalkine (FKN). PLT adhesion to HIMEC was
evaluated by fluorescence microscopy, and release of angiogenic factors (VEGF and soluble CD40L) was measured by ELISA. A matrigel
tubule formation assay was used to estimate PLT capacity to induce angiogenesis after co-culturing with HIMEC. TNF- up-regulated
ICAM-1, v3 and FKN expression on HIMEC. When thrombin-activated PLT were co-cultured with unstimulated HIMEC, PLT adhesion
increased significantly, and this response was further enhanced by HIMEC activation with TNF-. PLT adhesion to HIMEC was VCAM-1
and TF  independent but ICAM-1, FKN  and integrin v3 dependent. VEGF and sCD40L were undetectable in HIMEC cultures either
before or after TNF- stimulation. By contrast, VEGF and sCD40L release significantly increased when resting or activated PLT were 
co-cultured with TNF--pre-treated HIMEC. These effects were much more pronounced when PLT were derived from IBD patients.
Importantly, thrombin-activated PLT promoted tubule formation in HIMEC, a functional estimate of their angiogenic potential. In conclu-
sion, PLT adhesion to TNF--pre-treated HIMEC is mediated by ICAM-1, FKN and v3, and is associated with VEGF and sCD40L release.
These findings suggest that inflamed HIMEC may recruit PLT which, upon release of pro-angiogenic factors, actively contribute to
inflammation-induced angiogenesis.
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inflammation [3]. In addition to pro-inflammatory actions, IL-8
has been implicated in tumour angiogenesis and may be
secreted by colonic epithelial cells and microvessel EC [4].
Similarly, basic fibroblast growth factor (bFGF) may mediate
tumour necrosis factor (TNF)--induced angiogenesis both 
in vitro and in vivo [5]. In this respect, we have recently shown
that angiogenesis may be implicated in the pathogenesis 
of inflammatory bowel disease (IBD) [6]. In line with this
assumption, microvessel density is increased in IBD mucosal
tissues, a phenomenon that is mostly dependent upon height-
ened IL-8, bFGF and VEGF release [6]. In addition, angiogenesis
blockade may represent a new and promising therapeutic target
in experimental models of IBD [7, 8].
The CD40-CD40 ligand (CD40L) axis is a regulator and ampli-
fier of immune reactivity and contributes to leucocyte and
platelet (PLT) adhesion to inflamed intestinal EC [8–10]. CD40
expression is prominent in pathological conditions associated
with angiogenesis and inflammation, and ligation of CD40 on EC
and monocytes leads to production of bFGF and VEGF [11]. For
instance, CD40 engagement on synovial fibroblasts by CD40L-
expressing activated T cells up-regulates the production of 
VEGF, providing a potential explanation for the occurrence of
neovascularization in rheumatoid arthritis [12]. CD40L is over-
represented in patients with IBD, mainly reflecting enhanced
expression on the PLT surface and spontaneous release into the
circulation [10, 13]. Plasma sCD40L is particularly elevated 
in patients with active Crohn’s disease and ulcerative colitis 
compared with patients with inactive disease and with healthy
controls [10, 13].
IBD has been associated with PLT dysfunction, and increased
PLT aggregation to epinephrine, collagen and/or ADP [14].
Increased PLT expression of P-selectin [15] and elevation of
PLT-derived microparticles have been previously reported in
patients with IBD. In addition to qualitative abnormalities, PLT
are numerically elevated in patients with IBD in relation with
increased thrombopoietin and IL-6 serum levels [16, 17].
Interestingly, an increased tendency to form PLT-leucocyte
aggregates has been described both in the affected colonic
mucosa and in the peripheral blood of patients with active IBD,
but not in other chronic inflammatory disorders [18, 19]. PLT-
derived inflammatory and pro-angiogenic mediators such as
sCD40L and VEGF may be instrumental in the in vitro migration
and vessel-like organization of EC, pointing to a role for PLT in
inflammatory neoangiogenesis [20].
The present study was designed and conducted to determine
whether activated PLT may contribute to angiogenesis through an
enhanced adhesiveness to inflamed EC with subsequent release
of pro-angiogenic growth factors. We also addressed the poten-
tial molecular determinants of PLT–EC interactions that may 
contribute to angiogenesis and inflammation in the IBD microvas-
culature [21]. We show herein that PLT adhesion to inflamed
microvascular EC translates into an enhanced release of pro-
angiogenic mediators, providing clues on the potential role of
activated PLT in the promotion of inflammation-driven angiogen-
esis in the gut.
Materials and methods
Patient population
Patients with active IBD were studied after their informed consent. The
investigations were reviewed and approved by the local Ethical Committee.
All diagnoses were confirmed by clinical, radiological, endoscopic and his-
tological criteria, as previously detailed [10, 13]. Anatomical disease exten-
sion was assessed by radiological and endoscopic examination. Peripheral
blood samples were also obtained from consented healthy blood donors
and were used to isolate PLT for control experiments, as reported [13, 22].
Patients’ characteristics were summarized in Table 1.
Procurement and culture of HIMEC
Surgical specimens of colonic origin were used to isolate human intes-
tinal microvascular endothelial cells (HIMEC), as reported elsewhere 
[23, 24]. Briefly, after enzymatic digestion of intestinal mucosal strips,
samples were gently compressed to extrude EC clumps, which adhered
to fibronectin-coated plates, and were subsequently cultured in
MCDB131 medium (Sigma Aldrich, St. Louis, MO, USA) supplemented
with 20% FBS, antibiotics, heparin, and EC growth factor. HIMEC were
routinely plated on fibronectin-coated wells of a 24-well cluster plate at a
density of 5  104/ml/well. For HIMEC activation, cells were supple-
mented with 100 IU/ml TNF- (R&D Systems, Oxon, UK). Cultures of
HIMEC were maintained at 37C in 5% CO2 and cells were used between
passages 3 and 10 [23].
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Isolation of PLT and PLT-HIMEC co-culture
PLT from normal donors were obtained by gel filtration of PLT-rich plasma
(PRP) onto Sepharose 2B columns (25  1 cm) equilibrated with a buffer
containing 20 mM Hepes, 135 mM NaCl, 5 mM KCl, 5 mM glucose, 0.2%
albumin (pH 7.4). Ethylenediaminetetraacetic acid (EDTA) disodium salt 
(1 mM final concentration) was added to the PRP prior to gel filtration to
minimize PLT activation during washing procedures. The resulting PLT
population was essentially free of contaminating erythrocytes (0.1%)
and peripheral blood mononuclear cells. In order to rule out PLT activation
due to the isolation procedure, PLT activation state was assessed before
and after isolation by measuring P-selectin expression levels, as previously
detailed [10]. The PLT count was adjusted to 1  105/l with washing
buffer in all the experiments [13, 25].
Confluent monolayers of HIMEC were incubated with either 2%
bovine serum albumin alone or 0.5 U/ml thrombin alone, or they were
overlaid with 100  106 resting or thrombin-activated PLT. Plates were
immediately centrifuged at 700 g for 2 min. to bring PLT and HIMEC in
close apposition. Each experiment was performed in duplicate. After 
4 hrs at 37C, supernatants were harvested, transferred to polypropylene
tubes, centrifuged at 1300 g at 4C for 10 min. to remove cell debris,
and stored at 	70C until analysis. In preliminary experiments, we
ensured, by visual microscopy and flow cytometry with PLT-specific
CD42b antibodies, that washings had removed virtually all PLT from the
HIMEC monolayers. At the end of the co-culture, HIMEC were washed
five times in cold phospate buffer saline (PBS) and a single cell suspen-
sion obtained using a detaching buffer (PBS, 20 mmol/l HEPES, pH 7.4,
10 mmol/l EDTA and 0.5% bovine serum albumin) for 10 min. each on
ice and at 37C, followed by vigorous pipetting.
Release of pro-angiogenic factors
VEGF-A and sCD40L levels in culture supernatants were measured in trip-
licate with commercially available ELISA, following the manufacturer’s
instructions. The limits of detection were as follows: 9 pg/ml VEGF-A and
10.1 pg/ml sCD40L.
In vitro tube formation assay
EC tube formation was assessed using Matrigel™, a solubilized 
extracellular basement membrane matrix extracted from the Engelbreth-
Holm-Swarm mouse sarcoma, as detailed elsewhere [26]. Briefly, multi-
well dishes were coated with 250 l of complete medium containing 
5 mg/ml Matrigel™ and HIMEC re-suspended in complete growth medium
were seeded at a density of 5  104. Cells were cultured on Matrigel™ for
16 hrs and inverted phase-contrast microscopy was used to assess for-
mation of endothelial tube-like structures. Five high-power fields per con-
dition were examined and experiments were performed in duplicate.
Statistical analysis
The approximation of data distribution to normality was preliminarily
tested with statistics for kurtosis and symmetry. Results were presented as
mean and S.D. All comparisons were performed with the Student’s t-test
for paired or unpaired determinations or with the ANOVA, as appropriate. The
criterion for statistical significance was defined as P 
 0.05.
Results
The pro-inflammatory cytokine TNF- enhances
the expression of cell adhesion molecules (CAM)
on HIMEC
In a first set of experiments, we determined how the exposure of
HIMEC to TNF- would affect the expression pattern of a spectrum
of adhesion molecules deemed relevant for HIMEC interaction
with PLT. To this end, vascular cell adhesion molecule (VCAM)-1,
intercellular adhesion molecule (ICAM)-1, aV3 integrin, tissue
factor (TF) and fractalkine (FKN) expression was investigated by
flow cytometry on HIMEC that were exposed to TNF- in vitro for
16 hrs. As shown in Fig. 1A, TNF--treated HIMEC up-regulated
ICAM-1, aV3 integrin and FKN, and expressed de novo VCAM-1
and TF when compared to CAM levels on untreated HIMEC. The
analysis of the mean fluorescence intensity ratios indicated that
the magnitude of adhesion molecule induction by TNF- differed
significantly, with aV3 integrin and FKN being particularly respon-
sive to the pro-inflammatory stimulus applied to HIMEC (Fig. 1B).
Inflammation promotes PLT adhesion to HIMEC
To ascertain whether a prototypical inflammatory cytokine such as
TNF- was endowed with the ability to promote PLT adhesion to
HIMEC, 10  106 PLT from healthy control patients were co-cul-
tured with 50  103 HIMEC that were activated with TNF-, as
above detailed. To dissect the role of PLT activation status, if any,
in the interaction with HIMEC, PLT were treated with thrombin
prior to HIMEC co-culture.
The baseline adhesion of resting PLT to untreated HIMEC is
shown in Fig. 2, left part. The stimulation of HIMEC with TNF-
enhanced PLT adhesion (Fig. 2). Interestingly, activation with
thrombin further increased the number of adhering PLT to resting
HIMEC and, to an even greater extent, the number of PLT that
adhered to TNF--activated HIMEC (Fig. 2). It should be pointed
out that provision of TNF- to HIMEC per se was capable of
enhancing the adhesion of resting PLT compared to that recorded
with unstimulated HIMEC, as shown in Fig. 2. Collectively, these
studies suggest that a pro-inflammatory cytokine stimulus pro-
motes the adhesion of resting PLT to HIMEC and that this effect is
significantly enhanced by PLT activation prior to the co-culture.
PLT adhesion to inflamed HIMEC is mediated
through ICAM-I, aV3 and FKN
We next attempted to dissect the mechanism(s) that govern PLT
adhesion to HIMEC under the inflammatory conditions that we
established herein. Because provision of TNF- to HIMEC trans-
lates into the up-regulation of selected adhesion molecules, we
maintained PLT-HIMEC co-cultures either in the presence or
© 2011 The Authors
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absence of blocking antibodies directed against VCAM-1, ICAM-1,
aV3 integrin, TF and FKN. Co-cultures were also performed with
resting HIMEC and resting PLT (negative control for PLT adhesion)
and with TNF--stimulated HIMEC and thrombin-activated PLT
(positive control for PLT adhesion). As shown in Fig. 3, neutraliza-
tion of either surface ICAM-1, aV3 integrin, or FKN significantly,
albeit not completely, inhibited PLT adhesion to HIMEC. Conversely,
no changes in the number of adhering PLT were recorded in co-
cultures established in the presence of blocking antibodies to either
VCAM-1 or TF compared with the control co-cultures containing
TNF--activated HIMEC and thrombin-activated PLT. Collectively,
neutralization studies suggest that a restricted panel of adhesion
molecules is involved in the enhanced PLT adhesion to inflamed
endothelial surfaces in our system model.
PLT from patients with active IBD are particularly
effective at releasing pro-angiogenic growth 
factors upon co-culture with HIMEC
We also aimed to ascertain whether PLT interaction with inflamed
HIMEC may promote the release of pro-angiogenic growth factors.
To accomplish this goal, we initially measured the release of
VEGF-A and sCD40L in the supernatant of co-cultures established
with HIMEC and PLT from healthy donors. VEGF-A was unde-
tectable in the supernatant of unstimulated HIMEC, but was read-
ily measured in supernatants of resting PLT (Fig. 4). PLT activation
with thrombin translated into a significant up-regulation of VEGF-A
levels compared with those detected in the supernatant of resting
PLT. Of interest, pre-treatment of HIMEC with the pro-inflamma-
tory cytokine TNF- enhanced the release of VEGF-A in the co-cul-
ture with both resting and thrombin-activated PLT (Fig. 4).
We subsequently reproduced the above co-culture experi-
ments using PLT from patients with active IBD, either Crohn’s dis-
ease or ulcerative colitis. PLT from patients with IBD released
greater amounts of VEGF-A both spontaneously and following
activation with thrombin compared with equal numbers of PLT
from healthy controls (Fig. 4). Notably, VEGF-A production by
resting PLT was further enhanced in the co-cultures containing
TNF--activated HIMEC. Not unexpectedly, the highest release of
VEGF-A was detected in the co-cultures established with throm-
bin-activated PLT and TNF--activated HIMEC.
The same culture conditions were applied in further experi-
ments aimed at quantifying sCD40L production. As depicted in
© 2011 The Authors
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Fig. 1 Expression of adhesion molecules after exposure to
TNF-. HIMEC were treated with TNF-, and then labelled
with monoclonal antibodies directed against VCAM-I,
ICAM-I, integrin V3, TF and FKN prior to flow cytometry
analysis. A representative experiment out of six with simi-
lar results is shown in (A). Black histograms depict isotypic
controls. The mean fluorescence intensity ratios of his-
togram distributions recorded in these experiments have
been pooled and are shown as mean and S.D. in (B). *P 
0.05 and **P  0.01 compared with HIMEC that were not
challenged with TNF-.
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Fig. 5, PLT from healthy controls released sCD40L and this phe-
nomenon was significantly enhanced by PLT activation with
thrombin. Whereas TNF--activated HIMEC promoted sCD40L
release from unstimulated PLT, no such increase in sCD40L pro-
duction occurred in the co-cultures established with activated
PLT and TNF--stimulated HIMEC compared with those con-
taining activated PLT alone (Fig. 5). Interestingly, PLT from
patients with active IBD released significantly greater quantities
of sCD40L compared with PLT from healthy controls, both
spontaneously and following thrombin activation. Finally, the
co-culture of PLT from IBD patients with TNF--activated
HIMEC further promoted sCD40L secretion, as depicted in 
Fig. 5. Collectively, PLT isolated from patients with active IBD
were endowed with a greater capacity to secrete both VEGF-A
and sCD40L either untouched or following their in vitro activa-
tion with thrombin. No differences were found between PLTs
derived from Crohn’s disease or ulcerative colitis patients (data
not shown).
Activated PLT favour tubule formation in HIMEC
cultures
In a further set of functional studies, we wanted to determine
whether thrombin-activated PLT may induce tubule formation in
HIMEC. To answer this, HIMEC were cultured on a solubilized
extracellular basement membrane extract and used to assess the
formation of endothelial-like structures by inverted phase-con-
trast microscopy [26]. As clearly shown in Fig. 6A, tube-like
structures could be seen after co-culturing fluorescently labelled
resting HIMEC with thrombin-activated PLT derived from healthy
controls but not in cultures established with HIMEC alone.
Thrombin alone failed to induce tubule formation by HIMEC (data
not shown). Fluorescent microscopy experiments with PLT-
HIMEC co-cultures stained with different fluorochromes indicated
that activated PLT preferentially localized at endothelial luminal
surfaces, as shown in a 3-dimensional adhesion assay on
matrigel (Fig. 6B).
© 2011 The Authors
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Fig. 2 Assays of PLT adhesion to HIMEC. Prior to the adhesion assay, PLT and HIMEC were either left untouched or activated with thrombin and TNF-,
respectively, as detailed in ‘Materials and methods’. The bar graph (mean  S.D.) summarizes the results obtained in six independent experiments. 
*P  0.05 compared with PLT adhesion to resting HIMEC; **P  0.01 compared with adhesion of resting PLT to HIMEC; §P  0.01 compared with
adhesion of resting PLT to TNF--activated HIMEC.
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Discussion
It is presently believed that IBD results from the interaction of
genetic, environmental, microbial and immune factors.
Accumulating evidence suggests that non immune cells such as
mucosal EC, fibroblasts, neurons and PLT actively contribute to
IBD pathogenesis [27]. In particular, we and others have previ-
ously provided novel and substantial evidence that PLT are
dynamic participants in the multi-component system responsible
for mucosal inflammation and injury [28]. Since the number and
© 2011 The Authors
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Fig. 4 Release of VEGF upon co-culture of HIMEC with PLT from healthy controls and patients with active IBD. PLT from either healthy controls (n  8;
empty columns) or patients with active IBD (8 UC and 9 CD; shaded columns) were co-cultured with HIMEC that were either left untouched or activated
with TNF-. VEGF release was measured with conventional ELISA in culture supernatants. The bar graph (mean  S.D.) summarizes the results
obtained in six independent experiments.
Fig. 3 PLT adhesion to HIMEC after antibody-
mediated neutralization of adhesion molecules.
Neutralising antibodies to VCAM-I, TF, ICAM-1,
integrin V3 and FKN were provided to the
HIMEC-PLT co-cultures. The number of adher-
ing PLT was counted and plotted in the y-axis.
The adhesion of thrombin-activated PLT to TNF-
-activated HIMEC was measured as positive
control. The addition of neutralising antibodies
to ICAM-I, integrin V3 and FKN translated into
a statistically significant reduction of the num-
ber of adhering PLT. The bar graph (mean 
S.D.) summarizes the results obtained in six
independent experiments. *P  0.01 compared
with adhesion of activated PLT to TNF--acti-
vated HIMEC.
activation state of PLT are markedly increased in IBD patients, PLT
contained within the systemic circulation represent a potential risk
factor for triggering an inflammatory response at the intestinal
level. For these considerations, PLT are currently viewed as an
attractive target for therapeutic intervention [13, 22, 29]. In a dif-
ferent disease context such as multiple sclerosis, PLT-derived
VEGF reportedly sustains angiogenesis, a process that may be
exacerbated as a result of PLT interaction with the injured ECs [30].
CD40L, also referred to as gp39, is a cell surface molecule
largely restricted to activated CD4 T cells, and is also expressed
by human vascular EC, smooth muscle cells and macrophages.
The CD40-CD40L axis has been implicated in the pathogenesis of
several human diseases, including atherosclerosis [31], rheuma-
toid arthritis [12] and IBD [8]. PLT have been reported to trigger
CD40-dependent inflammatory responses in the IBD microvascu-
lature and to induce endothelial CAM up-regulation, chemokine
secretion and leucocyte recruitment [10]. However, the role of
activated PLT in inducing mucosal angiogenesis has not been
explored yet, although extensive data on PLT-microvasculature
interactions have been reported in mice [32]. Since PLT aggrega-
tion and microthrombi are frequent findings in the IBD microvas-
culature [28, 33, 34], it would be particularly important to gain
insights into the molecular determinants of such interaction in
human beings.
Our data show that human PLT adhesion to HIMEC mainly
occurs when PLT, HIMEC or both are activated, and that PLT-
HIMEC interactions are mediated by ICAM-1, aV3 integrin, and
FKN as suggested by antibody blockade experiments. Not unex-
pectedly, TNF-, a potent pro-inflammatory stimulus, induced
adhesion molecule expression on HIMEC, leading to the promo-
tion of PLT adhesion. FKN and aV3 integrin manifested the highest
degree of induction in response to TNF- stimulation, suggesting
that these CAM may be exquisitely sensitive to a pro-inflammatory
milieu. Remarkably, FKN has been shown to mediate the adhesion
of FKN receptor-expressing T cells to HIMEC, pointing to this mol-
ecule as a determinant of HIMEC interaction with both immune
and non-immune cells [35, 36].
In addition to adhering to the activated endothelium, PLT are
known to secrete a wide array of pro-inflammatory mediators [28].
In the present study, we focused mainly on angiogenic molecules
such as VEGF-A and sCD40L. As shown by the co-culture experi-
ments, PLT were the main source of both VEGF-A and sCD40L, and
PLT secretion was higher when PLT were activated with thrombin,
or maintained in co-culture with TNF--treated HIMEC, a finding
compatible with higher PLT adhesion and with enhanced PLT acti-
vation. Notably, PLT from patients with active IBD were particularly
prone to release pro-angiogenic VEGF-A and sCD40L, either spon-
taneously or in response to thrombin, when compared with PLT
J. Cell. Mol. Med. Vol 15, No 3, 2011
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Fig. 5 Release of sCD40L upon co-culture of HIMEC with PLT from healthy controls and patients with active IBD. PLT from either healthy controls 
(n  8; empty columns) or patients with active IBD (8 UC and 9 CD; shaded columns) were co-cultured with HIMEC that were either left untouched or
activated with TNF-. The release of sCD40L was measured with conventional ELISA in culture supernatants. The bar graph (mean  S.D.) summa-
rizes the results obtained in six independent experiments.
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from healthy volunteers. In addition, VEGF-A and sCD40L produc-
tion by PLT from patients with IBD were maximal upon co-culture
with TNF--activated HIMEC. Indeed, these in vitro experiments
might recapitulate an in vivo scenario, where PLT circulate in the
inflamed IBD microvasculature, encounter an activated endothe-
lium, adhere and get activated themselves, contributing to foster
intestinal inflammation [28]. When translating our findings to an 
in vivo context, it is conceivable that neither PLT adhesion to EC nor
PLT release of pro-angiogenic mediators perturb intestinal home-
ostasis under physiological conditions. This is backed by our
observation that both the number of resting PLT adhering to
HIMEC and the release of VEGF and sCD40L by resting PLT are sig-
nificantly lower compared with the data recorded with thrombin-
activated PLT, suggesting that in vivo PLT activation occurring in
patients with IBD is required to trigger PLT recruitment and adhe-
sion [9], and to foster the release of pro-angiogenic cytokines upon
interaction with the inflamed EC. Unequivocal evidence is now
available in favour of PLT activation in patients with IBD, including
an increased tendency to form PLT-leucocyte aggregates [37], an
increased PLT aggregation response to epinephrine, collagen and
ADP [14], and the ability of activated PLT to induce the formation
of reactive oxygen species by polymorphonuclear leucocytes [38].
It is thus tempting to speculate that PLT activation status will dic-
tate the outcome of PLT–EC interaction in vivo.
In addition, we explored the role of PLT as a novel cell type
involved in mediating angiogenesis. EC tube formation on base-
ment membranes replicates many of the steps in angiogenesis,
encompassing adhesion, migration, protease activity, alignment
and tube formation [39]. In our tubule formation assays with a
solubilized extracellular membrane matrix, the presence of
thrombin-activated PLT prompted robust angiogenesis, suggest-
ing a potential active role of PLT in mediating inflammation-
induced angiogenesis. We have recently shown that CD40L and
VEGF-A are crucial molecules that act at the cross-road between
angiogenesis and inflammation [7]. In support of this, preclini-
cal models of experimental IBD have shown that blockade 
of either CD40L or VEGF-A may induce significant amelioration
of experimental colitis, associated with dramatic inhibition of
inflammation-induced angiogenesis. Therefore, it is tempting to
speculate that such therapeutic effect could also result from the
inhibition of PLT-derived pro-angiogenic and pro-inflammatory
sCD40L and VEGF-A.
Collectively, our study indicates that PLT may serve as partners
for the promotion of angiogenesis and sheds some light into the
molecular determinants that drive inflammation-induced angio-
genesis. Whether PLT may be successfully targeted to limit pro-
angiogenic factor release and dampen inflammation in clinical IBD
will have to be tested by future clinical trials.
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Fig. 6 Tubule formation assay and visualization of PLT-HIMEC interaction. (A) PLT from healthy controls were either left untouched or activated with
thrombin. Tubule formation was evaluated as detailed in ‘Materials and methods’. One representative experiment out of six with similar results is shown.
(B) PLT from healthy controls were either left untouched or activated with thrombin. The interaction of HIMEC (green) and PLT (red) was visualized by
confocal microscopy. One representative experiment out of four with similar results is shown.
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